We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Beneficial Effects of Lactobacillus Reuteri DSM 17938 Supplementation on Asthmatic Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01241084
Recruitment Status : Completed
First Posted : November 16, 2010
Last Update Posted : October 3, 2011
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

Objective The aim of the trial is to evaluate the beneficial effects of the oral administration of the probiotic L. Reuteri (Reuterin®) on the airways allergic inflammation in children with mild to moderate persistent asthma.

Study design This is a randomized, double-blind, placebo controller trial. 50 children will be enrolled (age range 6-14 years), affected by mild to moderate persistent asthma based on the GINA Guidelines and allergic to acarus (Dermatophagoides farinae and D. pteronyssinus ++/+++). At the enrollment period all children have to show asthmatic symptoms and to be under antileukotrienes treatment (Montelukast 5mg/die) based on the GINA Guidelines. Any inhaling corticosteroids therapies have to be stopped 8 weeks before the trial beginning.

Patients will be randomly divided into 2 treatment groups:

Group A: 25 patients will take antileukotrienes + L. reuteri drops (108 CFU = 5 drops daily).

Group B: 25 patients will take antileukotrienes + placebo. At the enrollment period (T0), after the 1st and the 2nd month of supplementation (T1 and T2), and also 1 month after the supplementation end (T3), all patients will be clinically evaluated through spirometry, FeNO determination and exhale condensate analysis.

During the entire trial period the number of asthmatic exacerbations and the use of beta-2 antagonists will be monitored by a diary properly examined at T1, T2 and T3.

All children will be enrolled at the Asthma and Infant Respiratory Physiopathology unit "Michele Miraglia del Giudice" of the "F. Fede" Pediatric Department.

The analysis of the inflammatory markers on the exhaled condensate will be performer at T1, T2 and T3 in the Pharmacology unit of the Experimental Medicine Department.

During the trial it will be possible to administer only salbutamole MDI if it needed. If patients will be administered with any systemic corticosteroids they will exit from the trial.

At the enrolment period all patients will receive the completed information on the trial and the informed consent will be properly signed.


Condition or disease Intervention/treatment
Airways Allergic Inflammation of Asthmatic Children Dietary Supplement: Antileukotrienes + Lactobacillus reuteri Dietary Supplement: Antileukotrienes + Placebo

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Beneficial Effects of Lactobacillus Reuteri DSM 17938 Supplementation on the Airways Allergic Inflammation of Asthmatic Children
Study Start Date : June 2009
Primary Completion Date : December 2010
Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Placebo Comparator: Placebo
Antileukotrienes+Placebo
Dietary Supplement: Antileukotrienes + Placebo
Montelukast (5mg/die) + 5 drops of placebo daily for 2 months
Active Comparator: Lactobacillus reuteri
Antileukotrienes+Lactobacillus reuteri
Dietary Supplement: Antileukotrienes + Lactobacillus reuteri
Montelukast (5mg/die) + 1000000000 CFU per day (5 drops) for 2 months


Outcome Measures

Primary Outcome Measures :
  1. Beneficial effects of Lactobacillus reuteri supplementation on asthmatic children [ Time Frame: two months ]

    At the enrollment period all children have to show asthmatic symptoms and to be under antileukotrienes treatment (Montelukast 5mg/die) based on the GINA Guidelines. .

    At the enrolment period (T0), after the 1st and the 2nd month of supplementation (T1 and T2), and also 1 month after the supplementation end (T3), all patients will be clinically evaluated through spirometry, FeNO determination and exhale condensate analysis.

    During the entire trial period the number of asthmatic exacerbations and the use of beta-2 antagonists will be monitored by a diary properly examined at T1, T2 and T3.



Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Years to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Children with age range 6-14 years
  • Informed consent signed

Exclusion Criteria:

  • Participation to other clinical trials
  • Informed consent not signed
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01241084


Locations
Italy
AOU "Federico II" di Napoli
Napoli, Italy
Sponsors and Collaborators
Federico II University
Investigators
Principal Investigator: Michele Miraglia del Giudice, MD AOU "Federico II" di Napoli
More Information

Responsible Party: Prof. Michele Miraglia del Giudice, MD, Federico II University
ClinicalTrials.gov Identifier: NCT01241084     History of Changes
Other Study ID Numbers: Lr_Asthma
First Posted: November 16, 2010    Key Record Dates
Last Update Posted: October 3, 2011
Last Verified: September 2011

Keywords provided by Prof. Michele Miraglia del Giudice, Federico II University:
asthmatic children

Additional relevant MeSH terms:
Inflammation
Asthma
Pathologic Processes
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Leukotriene Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents